Dutoprol
- Generic Name: metroprolol
- Brand Name: Dutoprol
Dutoprol (Metroprolol) side effects drug center
Dutoprol Side Effects Center
What Is Dutoprol?
Dutoprol (metoprolol succinate extended release/hydrochlorothiazide) is a combination of a beta1-selective (cardioselective) adrenoceptor-blocking agent and a diuretic used to treat hypertension, to lower blood pressure.
What Are Side Effects of Dutoprol?
Common side effects of Dutoprol include:
- inflammation of the nose and throat,
- runny or stuffy nose,
- sore throat,
- fatigue,
- tiredness,
- dizziness,
- back pain,
- nausea,
- slow heart rate, and
- low blood potassium (hypokalemia).
Dosage for Dutoprol?
Dosing of Dutoprol is individualized considering baseline and target blood pressure and any experience with the individual drugs. The usual initial dose of metoprolol succinate extended release is 25 to 100 mg daily in a single dose. Hydrochlorothiazide is effective in doses of 12.5 mg to 50 mg once daily.
What Drugs, Substances, or Supplements Interact with Dutoprol?
Dutoprol may interact with cisapride, dofetilide, fingolimod, lithium, lumefantrine, quinidine, propafenone, SSRI antidepressants, St. John's wort, cough-and-cold products, diet aids, or NSAIDs. Tell your doctor all medications and supplements you use.
Dutoprol During Pregnancy and Breastfeeding
During pregnancy, Dutoprol should be used only if prescribed. A small amount of metoprolol passes into breast milk. Thiazides pass into breast milk. Consult your doctor before breastfeeding.
Additional Information
Our Dutoprol (metoprolol succinate extended release/hydrochlorothiazide) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Dutoprol Professional Information
SIDE EFFECTS
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.
Metoprolol Succinate Extended Release/Hydrochlorothiazide
The metoprolol succinate extended release and hydrochlorothiazide combination was evaluated for safety in 891 patients with hypertension in clinical trials. In a randomized, double-blind, placebo-controlled, factorial trial (Study 1), 843 patients were treated with various combinations of metoprolol succinate (doses of 25 to 200 mg) and hydrochlorothiazide (doses of 6.25 to 25 mg) [see Clinical Studies]. Adverse events which occurred more than 1% more frequently in patients treated with DUTOPROL than placebo were: nasopharyngitis (3.4% vs 1.3%) and fatigue (2.6% vs 0.7%).
The adverse reactions of metoprolol succinate extended release are a mixture of dose-dependent phenomena (primarily bradycardia and fatigue) and those of hydrochlorothiazide are a mixture of dose-dependent (primarily hypokalemia) and dose independent phenomena (e.g., pancreatitis), the former much more common than the latter. Therapy with DUTOPROL will be associated with both sets of dose independent reactions.
Laboratory Abnormalities
Liver Enzyme Tests - Increases in liver enzymes or serum bilirubin.
Post-Marketing Experience
The following adverse reactions have been identified during post-approval use of DUTOPROL, metoprolol succinate extended release, and/or hydrochlorothiazide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or establish a causal relationship to drug exposure.
Metoprolol
The following adverse reactions have been reported for immediate release metoprolol tartrate. Most adverse reactions have been mild and transient.
Central Nervous System: Confusion, short-term memory loss, headache, somnolence, nightmares, insomnia, anxiety/nervousness, hallucinations, paresthesia, dizziness
Cardiovascular: Shortness of breath, bradycardia, cold extremities; arterial insufficiency (usually of the Raynaud type), palpitations, peripheral edema, syncope, chest pain
Respiratory: Dyspnea
Gastrointestinal: Diarrhea, nausea, dry mouth, gastric pain, constipation, flatulence, heartburn, hepatitis, vomiting
Hypersensitivity Reactions: Pruritus, rash
Miscellaneous: Musculoskeletal pain, arthralgia, blurred vision, decreased libido, male impotence, tinnitus, reversible alopecia, dry eyes, worsening of psoriasis, Peyronie's disease, sweating, photosensitivity, taste disturbance, depression
Other Beta-Adrenergic Blockers
In addition, adverse reactions not listed above, that have been reported with other beta-adrenoceptor blockers and should be considered potential adverse reactions to DUTOPROL.
Central Nervous System: Reversible mental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation for time and place, emotional lability, clouded sensorium, and decreased performance on neuropsychometrics
Hematologic: Non-thrombocytopenic purpura, thrombocytopenic purpura
Hypersensitivity Reactions: Laryngospasm, and respiratory distress
Hydrochlorothiazide
Adverse reactions that have been reported with hydrochlorothiazide are listed below:
Body as a Whole: Weakness
Cardiovascular: Orthostatic hypotension
Digestive: Pancreatitis, jaundice (intrahepatic cholestatic jaundice), sialadenitis, cramping, gastric irritation, anorexia
Hematologic: Aplastic anemia, agranulocytosis, leukopenia, hemolytic anemia, thrombocytopenia
Hypersensitivity Reactions: Anaphylactic reactions, necrotizing angiitis (vasculitis and cutaneous vasculitis), respiratory distress including pneumonitis and pulmonary edema, photosensitivity, fever, urticaria
Metabolic: Glycosuria
Musculoskeletal: Muscle spasm
Nervous System/Psychiatric: Vertigo, paresthesias, restlessness
Renal: Interstitial nephritis
Skin: Erythema multiforme including Stevens-Johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis
Non-melanoma Skin Cancer
Hydrochlorothiazide is associated with an increased risk of non-melanoma skin cancer. In a study conducted in the Sentinel System, increased risk was predominantly for squamous cell carcinoma (SCC) and in white patients taking large cumulative doses. The increased risk for SCC in the overall population was approximately 1 additional case per 16,000 patients per year, and for white patients taking a cumulative dose of ≥50,000mg the risk increase was approximately 1 additional SCC case for every 6,700 patients per year.
Special Senses: Transient blurred vision, xanthopsia
Read the entire FDA prescribing information for Dutoprol (Metroprolol)
&Copy; Dutoprol Patient Information is supplied by Cerner Multum, Inc. and Dutoprol Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.